Setmelanotide Guide
FDA-Approved MC4R Agonist for Genetic
Complete guide to Setmelanotide. Setmelanotide (brand name IMCIVREE) is an FDA-approved melanocortin 4 receptor (MC4R) agonist developed by Rhythm.
FDA-Approved MC4R Agonist for Genetic Obesity (IMCIVREE)
Setmelanotide (brand name IMCIVREE) is an FDA-approved melanocortin 4 receptor (MC4R) agonist developed by Rhythm Pharmaceuticals. Unlike GLP-1 medications that target appetite through incretin pathways, setmelanotide directly activates the MC4R pathway in the hypothalamus — the brain\'s primary appetite regulation center. It is specifically approved for rare genetic obesity disorders caused by POMC, PCSK1, or LEPR deficiency, with expansion studies ongoing for Bardet-Biedl syndrome and other genetic conditions. Use the Shotlee app to track your current protocol and build baseline data for whatever comes next.
What Is Setmelanotide?
Setmelanotide (brand name IMCIVREE) is an FDA-approved melanocortin 4 receptor (MC4R) agonist developed by Rhythm Pharmaceuticals. Unlike GLP-1 medications that target appetite through incretin pathways, setmelanotide directly activates the MC4R pathway in the hypothalamus — the brain\'s primary appetite regulation center. It is specifically approved for rare genetic obesity disorders caused by POMC, PCSK1, or LEPR deficiency, with expansion studies ongoing for Bardet-Biedl syndrome and other genetic conditions.
Track your current protocol in Shotlee while this science evolves. Having clean historical data means you can compare outcomes with precision if you ever switch medications.
How It Works
MC4R Activation
Directly targets brain appetite center. Restores broken satiety signaling. Bypasses incretin pathways. Track hunger patterns in Shotlee
Genetic Obesity Focus
POMC deficiency obesity. PCSK1 deficiency obesity. LEPR deficiency obesity. Log genetic therapy in Shotlee
Unique Mechanism
Not a GLP-1 or amylin drug. Melanocortin pathway restoration. Daily subcutaneous injection. Monitor all protocols in Shotlee
Why This Matters
Setmelanotide is the first precision medicine for genetic obesity, directly restoring the broken MC4R signaling that causes insatiable hunger in affected patients. It represents a fundamentally differ
Clinical Data
POMC/PCSK1 (52 wks)
~10%+
Hunger Reduction
Dramatic
Significant weight loss and dramatic hunger reduction in patients with POMC or PCSK1 deficiency obesity.
Side Effects
Injection site reactions
Skin hyperpigmentation (common)
Spontaneous penile erections (males)
Track all effects in Shotlee
Vital Protocol FAQs
Is Setmelanotide for general obesity?
Currently, IMCIVREE is FDA-approved specifically for rare genetic obesity caused by POMC, PCSK1, or LEPR pathway deficiencies. Expansion studies for other genetic obesity forms are ongoing. Track your
How is it different from GLP-1 drugs?
Completely different mechanism. Setmelanotide activates MC4R in the brain\'s hypothalamus to restore broken appetite signaling, while GLP-1 drugs work through incretin hormone pathways. Use Shotlee to
Guide FAQs
Complete guide to Setmelanotide. Setmelanotide (brand name IMCIVREE) is an FDA-approved melanocortin 4 receptor (MC4R) agonist developed by Rhythm.
Yes. Shotlee supports tracking Setmelanotide doses, side effects, and health metrics. It is free to use.
References
Track Your Setmelanotide Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.
🚀 Use Shotlee for Free